Skip to main content
SpringerLink
Log in

Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study

  • IM - ORIGINAL
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Transthyretin-related (ATTR) cardiac amyloidosis is currently lacking a disease-modifying therapy. Despite demonstration of effectiveness in halting amyloid deposition, no study focused on epigallocatechin-3-gallate (EGCG) impact on patient survival. We sought to explore prognostic impact of EGCG in a cohort of lone cardiac ATTR patients. From the Florence Tuscan Regional Amyloid Centre database, we retrospectively selected ATTR patients treated with EGCG (675mg daily dose) for a minimum of 9 months, between March 2013 and December 2016. As a control group, we selected ATTR patients who received guideline-directed medical therapy alone. End point of the study was time to all cause death or cardiac transplantation. Sixty-five patients (30 treatment groups vs. 35 control groups) had a median follow-up of 691 days. There were no differences in baseline characteristics between groups. Five deaths occurred in EGCG group versus eight in control group; one patient underwent effective cardiac transplantation in EGCG group. There was no difference in survival estimates between EGCG and control group (60 ± 15% vs. 61 ± 12%, p = 0.276). EGCG was well tolerated, without major safety concerns. In a real-world cohort of ATTR patients with lone cardiac involvement, EGCG was a safe therapeutic option, but was not associated with survival improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Perfetto F, Cappelli F, Bergesio F, Ciuti G, Porciani MC, Padeletti L (2013) Moggi Pignone A cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8:191–203

    Article  PubMed  Google Scholar 

  2. Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641–2654

    Article  PubMed  CAS  Google Scholar 

  3. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014–1020

    Article  PubMed  Google Scholar 

  4. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. JAMA 310:2658–2667

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G (2012 Jun) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34–36

    Article  PubMed  CAS  Google Scholar 

  6. Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C (2017) ATTR-ACT study investigators. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003815

  7. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM et al (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109

    Article  PubMed  PubMed Central  Google Scholar 

  8. Adams D, Suhr OB, Dyck PJ, Litchy W, Leahy RG, Chen J, Gollob J (2017) Coelho T Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17:181

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A (2008) Wanker EE EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat Struct Mol Biol 15:558–566

    Article  PubMed  CAS  Google Scholar 

  10. Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Ba G, Saraiva MJ, Almeida MR (2009) Binding of epigallocatechin- 3-gallate to transthyretin modulates) its amyloidogenicity. FEBS Lett 19(583):3569–3576

    Article  CAS  Google Scholar 

  11. Ferreira N, Saraiva MJ (2012) Almeida MR epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: ‘‘in vivo’’ evidence from FAP mice models. PLoS ONE 7(1):e29933

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Ferreira N, Saraiva MJ, Almeida M (2012) Natural polyphenols as modulators of TTR Amyloidogenesis in vitro and in vivo evidences towards therapy. Amyloid 19(S1):39–42

  13. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Rocken C, Wanker EE, Dengler TJ, Altland K, Katus HA (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101(10):805–813

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99:483–490

  15. Aus dem Siepen F, Buss SJ, Andre F, Seitz S, Giannitsis E, Steen H, Katus HA, Kristen AV (2015) Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 104(8):640–647

  16. Aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV (2015) Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Design Dev Therapy 9 6319–6325

  17. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS (2010) Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 48(1):409–416

    Article  PubMed  CAS  Google Scholar 

  18. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404–2412

    Article  PubMed  CAS  Google Scholar 

  19. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2017) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx589

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1–39.e14

  21. Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 79:319–328

    Article  PubMed  Google Scholar 

  22. Cappelli F, Frusconi S, Bergesio F, Grifoni E, Fabbri A, Giuliani C, Falconi S, Bonifacio S, Perfetto F (2016) The Val142Ile transthyretin cardiac amyloidosis: not only an afro American pathogenic variant? A single center Italian experience. J Cardiovasc Med 2016 17(2):122–5.44

  23. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013 Feb) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528

    Article  PubMed  CAS  Google Scholar 

  24. Perfetto F, Cappelli F, Bergesio F (2011 Jun) Asymptomatic homozygous gene carrier in afamily with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? J Cardiovasc Med (Hagerstown). 12(6):450–451

    Article  Google Scholar 

  25. Hunstein W (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tuscan Regional Amyloid Center, Careggi University Hospital, Florence, Italy

    Francesco Cappelli, Paola Angelotti, Silvia Farsetti & Federico Perfetto

  2. Interventional Structural Cardiology Division, Careggi University Hospital, Florence, Italy

    Francesco Cappelli, Raffaele Martone, Giulia Taborchi, Sofia Morini, Simone Bartolini & Carlo Di Mario

Authors
  1. Francesco Cappelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raffaele Martone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulia Taborchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sofia Morini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simone Bartolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paola Angelotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Silvia Farsetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carlo Di Mario
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Federico Perfetto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Cappelli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cappelli, F., Martone, R., Taborchi, G. et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med 13, 873–880 (2018). https://doi.org/10.1007/s11739-018-1887-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-018-1887-x

Keywords

Search

Navigation